Reference Detail

Ref Type Journal Article
PMID (23258168)
Authors Anastas JN, Moon RT
Title WNT signalling pathways as therapeutic targets in cancer.
Journal Nature reviews. Cancer
Vol 13
Issue 1
Date 2013 Jan
URL
Abstract Text Since the initial discovery of the oncogenic activity of WNT1 in mouse mammary glands, our appreciation for the complex roles for WNT signalling pathways in cancer has increased dramatically. WNTs and their downstream effectors regulate various processes that are important for cancer progression, including tumour initiation, tumour growth, cell senescence, cell death, differentiation and metastasis. Although WNT signalling pathways have been difficult to target, improved drug-discovery platforms and new technologies have facilitated the discovery of agents that can alter WNT signalling in preclinical models, thus setting the stage for clinical trials in humans.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
CTNNB1 T41I CTNNB1 Inhibitor
CTNNB1 A13T CTNNB1 Inhibitor
CTNNB1 A43T CTNNB1 Inhibitor
CTNNB1 I35T CTNNB1 Inhibitor
CTNNB1 S45N CTNNB1 Inhibitor
CTNNB1 S33C CTNNB1 Inhibitor
CTNNB1 A39T CTNNB1 Inhibitor
CTNNB1 H36Y CTNNB1 Inhibitor
CTNNB1 I35N CTNNB1 Inhibitor
CTNNB1 S33A CTNNB1 Inhibitor
CTNNB1 I35S CTNNB1 Inhibitor
CTNNB1 T41A CTNNB1 Inhibitor
CTNNB1 S33N CTNNB1 Inhibitor
CTNNB1 D32G CTNNB1 Inhibitor
CTNNB1 G34R CTNNB1 Inhibitor
CTNNB1 V22A CTNNB1 Inhibitor
CTNNB1 S33P CTNNB1 Inhibitor
CTNNB1 A21T CTNNB1 Inhibitor
CTNNB1 S45T CTNNB1 Inhibitor
CTNNB1 K335I CTNNB1 Inhibitor
CTNNB1 G38P CTNNB1 Inhibitor
CTNNB1 S45P CTNNB1 Inhibitor
CTNNB1 S33L CTNNB1 Inhibitor
CTNNB1 S37T CTNNB1 Inhibitor
CTNNB1 S37C CTNNB1 Inhibitor
CTNNB1 act mut CTNNB1 Inhibitor
CTNNB1 G34A CTNNB1 Inhibitor
CTNNB1 S45C CTNNB1 Inhibitor
CTNNB1 A43P CTNNB1 Inhibitor
CTNNB1 P44_S45del CTNNB1 Inhibitor
CTNNB1 G34V CTNNB1 Inhibitor
CTNNB1 S33F CTNNB1 Inhibitor
CTNNB1 S37Y CTNNB1 Inhibitor
CTNNB1 S45del CTNNB1 Inhibitor
CTNNB1 W383R CTNNB1 Inhibitor
CTNNB1 D32N CTNNB1 Inhibitor
CTNNB1 S45F CTNNB1 Inhibitor
CTNNB1 G48D CTNNB1 Inhibitor
CTNNB1 S37P CTNNB1 Inhibitor
CTNNB1 S45Y CTNNB1 Inhibitor
CTNNB1 S33T CTNNB1 Inhibitor
CTNNB1 S33Y CTNNB1 Inhibitor
CTNNB1 S37A CTNNB1 Inhibitor
CTNNB1 S45A CTNNB1 Inhibitor
CTNNB1 D32E CTNNB1 Inhibitor
CTNNB1 H36P CTNNB1 Inhibitor
CTNNB1 W25_D32del CTNNB1 Inhibitor
CTNNB1 D32V CTNNB1 Inhibitor
CTNNB1 G34E CTNNB1 Inhibitor
CTNNB1 E67K CTNNB1 Inhibitor
CTNNB1 D32A CTNNB1 Inhibitor
CTNNB1 D32H CTNNB1 Inhibitor
CTNNB1 D32Y CTNNB1 Inhibitor
CTNNB1 P44A CTNNB1 Inhibitor
CTNNB1 N387K CTNNB1 Inhibitor
CTNNB1 S37F CTNNB1 Inhibitor
CTNNB1 A39G CTNNB1 Inhibitor
CTNNB1 E54K CTNNB1 Inhibitor
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
S45C missense gain of function - predicted CTNNB1 S45C lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt). S45C has not been characterized, however other S45 “hotspot” mutations are activating thus, S45C is predicted to result in a gain of Ctnnb1 function (PMID: 15579438, PMID: 23258168).
S45N missense gain of function - predicted CTNNB1 S45N lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt). S45N has not been characterized, however, other S45 “hotspot” mutations are activating thus, S45N is predicted to result in a gain of Ctnnb1 function (PMID: 15579438, PMID: 23258168).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References